July 14, 2022
1 min watch
Save
VIDEO: ‘Revolutionary’ treatment findings in early-stage lung cancer presented at ASCO
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Ravi Salgia, MD, PhD, spoke with Healio about a study assessing the safety and efficacy of three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy compared with two cycles in patients with early-stage lung cancer.
The findings were presented at ASCO Annual Meeting.
The study was “revolutionary for us to think about,” according to Salgia, medical oncologist, professor and Arthur & Rosalie Kaplan Chair of the medical oncology and therapeutics research department at City of Hope.
References:
- Qiu F, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Salgia reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.